human cd34 pe conjugated antibody  (R&D Systems)

Journal: bioRxiv

Article Title: Preclinical Efficacy of Tasquinimod in Myelodysplastic Neoplasms: Restoring Erythropoiesis and Mitigating Bone Loss

doi: 10.1101/2025.07.01.660147

Figure Lengend Snippet: MSCs were pre-treated with S100A9 and/or TASQ for seven days and co-cultured with freshly isolated CD34+ HSPCs. a Representative images of CAF-C (highligted with purple circles) for each condition. b Quantification of CAF-C after one, two, three and four weeks. Pooled data from N=3 MDS MSC/HSPC co-culture experiments are shown as mean ± SD, *p< 0.05 for S100A9 vs. S100A9+TASQ. c, d After one week of co-culture, a CFU assay was performed for 14 days in methylcellulose medium, with or without continuing treatment. Colonies were classified by using the StemVision system. Cumulative data from 4 experiments are shown as mean ± SD, *p< 0.05, ****p< 0.0001 by two-way ANOVA with Tukey’s multiple comparisons test.

Article Snippet: HSPCs were isolated using CD34 antibody-conjugated magnetic beads, according to the manufacturer’s instructions (Miltenyi Biotec).

Techniques: Cell Culture, Isolation, Co-Culture Assay, Colony-forming Unit Assay

Journal: bioRxiv

Article Title: Preclinical Efficacy of Tasquinimod in Myelodysplastic Neoplasms: Restoring Erythropoiesis and Mitigating Bone Loss

doi: 10.1101/2025.07.01.660147

Figure Lengend Snippet: MDS and healthy donor MSCs were pre-treated with S100A9 and/or TASQ for seven days and co-cultured with freshly isolated healthy BM CD34 + HSCs. a Flow cytometry analysis of CD71 + erythroid progenitors in the CD34 - /CD45 - fraction shows a significant increase in MSC co-cultures treated with Epo and TASQ. b The CD34 + /CD45 + fraction is significantly reduced in TASQ-treated MSC co-cultures, similar to Epo-treated co-cultures, but remains unaffected in HSC mono-cultures. c The CD45 + /CD34 + /HLA-DR + myeloid progenitor population is significantly elevated in MSC co-cultures, with TASQ reducing its frequency across differentiation conditions. d-f Monocyte subset analysis reveals that TASQ decreases CD14 + /CD16 - classical and CD14 + /CD16 + intermediate monocytes in MSC co-cultures, while increasing CD14 dim /CD16 + non-classical monocytes. Data from n=3-4 experiments are shown as mean ± SD, *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001 by two-way ANOVA with Sidak’s multiple comparisons test.

Article Snippet: HSPCs were isolated using CD34 antibody-conjugated magnetic beads, according to the manufacturer’s instructions (Miltenyi Biotec).

Techniques: Cell Culture, Isolation, Flow Cytometry

Journal: Science Advances

Article Title: KRAS G12V /HLA-A*02:01–targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors

doi: 10.1126/sciadv.aea2511

Figure Lengend Snippet: ( A ) Specificity screening of 11 positive clones against KRAS(WT)-HLA-A*02:01 and KRAS(G12V)-HLA-A*02:01 tetramers using enzyme-linked immunosorbent assay (ELISA; n = 3 independent experiments). ( B ) Antibody titration curves of selected clones, monoclonal antibody (mAb) A4 and B9, were measured by ELISA ( n = 3 independent replicates). OD 450 , optical density at 450 nm. ( C ) Schematic of CAR constructs showing CD19-, A4-, and B9-specific architectures. ( D ) Transduction efficiency was assessed on the basis of CD34 expression using flow cytometry ( n = 3 biological replicates). ( E ) Representative flow cytometry histograms showing CAR-positive populations after magnetic enrichment. ( F ) Frequency quantification of the indicated cell subsets by flow cytometry ( n = 3 biological replicates; ≥20,000 events analyzed per replicate). Data represent the means ± SD. Significance by two-way analysis of variance (ANOVA) with Tukey’s post hoc test: *** P < 0.001. TTE, terminally differentiated effector T cells; TEM, effector memory T cells; TCM, central memory T cells.

Article Snippet: Antibodies used in this study included human CD34 PE-conjugated antibody (R&D Systems, FAB7227P; RRID: AB_10973177), mouse immunoglobulin G1 (IgG1) PE-conjugated isotype control (R&D Systems, IC002P; RRID:AB_357242), fluorescein isothiocyanate (FITC) anti-human CD45RA (BioLegend, 983002; RRID: AB_2650650), APC anti-human CD197 (CCR7) (BioLegend, 353213; RRID: AB_10915474), FITC mouse IgG2b κ isotype control (BioLegend, 402207; RRID: AB_3097051), APC mouse IgG2a κ isotype control (BioLegend, 981906; RRID: AB_3097032), and FITC anti-human HLA-A2 (BioLegend, 343303; RRID: AB_1659246).

Techniques: Clone Assay, Enzyme-linked Immunosorbent Assay, Titration, Construct, Transduction, Expressing, Flow Cytometry

Journal: Nature medicine

Article Title: TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.

doi: 10.1038/s41591-024-03326-7

Figure Lengend Snippet: Fig. 3 | Lymph node biopsy. a–e, Lymph node biopsy samples after AUTO4 infusion for patient ID 01 (day 19) (a), 09 (day 100) (b), 22 (day 7) (c), 55 (day 12) (d) and 59 (day 8) (e). The main images show formalin-fixed, paraffin-embedded (FFPE) tissue sections of a T cell lymphoma stained by double IF with anti-CD34 (Q/BenD10), which stains RQR8 (red), and CD3 (yellow), which detects

Article Snippet: Cells were washed and resuspended in a surface stain master mix containing anti-CD45 PerCP-Cy 5.5 (332784Biol, BD), anti-CD3 BV510 (300448, BioLegend), anti-CD4 BV605 (344646, BioLegend), anti-CD8 PE-Cy7 (335822, BD), anti-CD19 BV786 (563325, BD), anti-TCR beta 1 AF488 (Santa Cruz Biotechnology), CD34 PE (FAB7227P, R&D systems) and anti-TRBC2 biotin (Autolus).

Techniques: Formalin-fixed Paraffin-Embedded, Staining

Journal: Exploration of medicine

Article Title: The association between circulating CD34+CD133+ endothelial progenitor cells and reduced risk of Alzheimer’s disease in the Framingham Heart Study

doi: 10.37349/emed.2024.00216

Figure Lengend Snippet: Examination of the relationship between different circulating progenitor or mature endothelial cells and the risk of AD/dementia by using Cox proportional hazards regression models after adjusting for covariates

Article Snippet: Then, PBMCs were isolated via Ficoll (General Electric) gradient centrifugation, counted, incubated with FcR blocking antibodies (Miltenyi Biotec), labeled with anti-human KDR PE antibody (R&D Systems), anti-human CD34 FITC antibody (BD Biosciences), anti-human CD133 APC antibody (BD Biosciences).

Techniques: